Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
2022年10月2日 - 8:00PM
JCN Newswire
PT Bio Farma (Persero), the holding company for pharmaceutical
state-owned enterprises (SOEs), will export its novel Oral Polio
Vaccine type 2 (nOPV2) having secured a purchase contract with the
United Nations Children's Fund (UNICEF) for 2022 & 23. Under
the contract, Bio Farma will export its oral polio vaccines based
on purchase requests from UNICEF via multilateral contract
agreement for the years 2022 & 23.
Indonesian State-Owned Enterprises (SOEs) Minister Erick Thohir has
said, "In line with the theme of the Indonesian G20 Presidency,
"Recover Together, Recover Stronger", it is important for
Indonesia's state-owned enterprises to lead with concrete actions
realized through strategic initiatives and large-scale
transformations to create global impacts."
Honesti Basyir, President Director of Bio Farma, said, "UNICEF
procures nOPV2 under a multilateral supply agreement as part of a
global effort to prevent spread of the polio disease. Bio Farma
will provide its annual production to the global nOPV2 stockpile,
which is a contribution to the global health industry, as we are
able to manufacture stockpiles that fulfill world needs. In turn,
we will fulfill individual deliveries to target countries or
regions following UNICEF request."
The nOPV2 vaccine received an Emergency Use of Listing (EUL) from
the World Health Organization (WHO) in November 2020, the first
ever vaccine certified for emergency use, adding to Bio Farma's
portfolio of products that were already available globally. It was
initially used to combat outbreaks of circulating vaccine-derived
polio viruses (cVDPVs) in a number of African and East
Mediterranean countries.
Bio Farma's nOPV2 vaccine is now distributed internationally,
ex-Indonesia, as Indonesia has been polio-free since 2014. Target
countries in Africa for the vaccine have included Algeria,
Cameroon, Kongo, Ethiopia, Gambia, Ghana, Nigeria, Senegal, and
Uganda. In Europe, it is administered in Israel and Ukraine, and in
the Middle East, in Egypt, Iran, Somalia and Yemen.
According to Honesti, nOpV2 vaccine is a result of collaboration
between Bio Farma and several international research institutes,
including Bill and Melinda Gates Foundation (BMGF), PATH, and the
WHO. Bio Farma has since become the main supplier of polio vaccines
in the world, and currently contributes 67% of the global
stockpile, while Bio Farma's laboratories have become the reference
for sampling polio vaccines in the world.
In manufacturing the nOPV2 vaccine, Bio Farma collaborated with
world-class institutions like the Bill and Melinda Gates Foundation
(BMGF), the PATH, and the WHO. Bio Farma has since become the main
supplier of polio OPV vaccines in the world, and currently
contributes 67% of the global OPV stockpile.
Bio Farma's Laboratories have also been widely acknowledged as
reference labs for poliovirus testing, while Bio Farma's success in
producing and exporting the nOPV2 vaccines shows the Indonesian
company fully contributing to the world health sector, apart from
providing the necessary vaccines at home in Indonesia.
In Line with G20
Honesti said Bio Farma's provision of vaccines is in line with a
main pillar of the Indonesian G20 Presidency (2021-22), Global
Health Architecture. Through its G20 Presidency, Indonesia has
showcased its success in controlling the Covid-19 pandemic and
maintaining public health and steady economic growth through
vaccination. Bio Farma has been a front liner in the
government-initiated vaccination program.
Bio Farma has been ready to mass-produce its IndoVac brand Covid-19
vaccine.* On September 24, an Emergency Use of Authorization (EUA)
was granted by the Indonesian Food and Drug Authority (BPOM),
following the halal certification from the Indonesian Ulema Council
(LPPOM MUI), and the Halal Certification Agency (BPJPH).
With this EUA and certification, mass production of IndoVac is
beginning immediately, as preparation work for the first batch was
already in place at the company's facility in Bandung. Bio Farma
plans to increase its production capacity to 40 million doses next
year, and to 100 million doses by 2024, given demand in the global
markets.
Bio Farma hopes that its IndoVac vacciness can contribute to
reducing the spread of Covid-19 in the world, much as its nOPV2
vaccine has contributed to reducing the polio spread.
About Bio Farma
PT Bio Farma (Persero), the holding company for pharmaceutical
state-owned enterprises (SOEs), offers end-to-end services across
the healthcare spectrum - from pharmaceutical research and
development, manufacturing and distribution to the operation of
retail pharmacies, health clinics and clinical laboratories. Bio
Farma's head office and production facilities are in Bandung, West
Jawa, with a representative office in Jakarta, Indonesia's capital
city.
Bio Farma is a leading human vaccine producer with production
capacity of 3.2 billion doses per year, and has exported its
vaccines to more than 150 countries. Bio Farma recently became the
parent through merger of listed state-owned pharmaceutical
companies PT Kimia Farma Tbk (IDX: KAEF), PT Indofarma Tbk (IDX:
INAF) and PT Phapros Tbk (IDX: PEHA). For further information,
please visit www.biofarma.co.id
Media contact:
R. Rifa Herdian
PT Bio Farma (Persero)
Corporate Secretary & Investor Relations
Tel: +62-81-2542-8844
Email: rifaherdian@biofarma.co.id
* 9/11/22: "Bio Farma ready to mass produce IndoVac brand Covid-19
vaccine"
https://www.acnnewswire.com/press-release/english/77878/indonesia's-bio-farma-ready-to-produce
Copyright 2022 JCN Newswire . All rights reserved.